第 1/4 張圖片
第 1/4 張圖片
Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mul..
US $29.98
大約HK$ 233.38
狀況：
全新
全新，未閱讀過和使用過的書籍，狀況完好，不存在缺頁或內頁受損。
運費：
US $4.99（大約 HK$ 38.84） USPS Media MailTM.
所在地：Fairhope, Alabama, 美國
送達日期：
估計於 9月28日, 六至 10月1日, 二之間送達 運送地點 43230
退貨：
30 日退貨. 由買家支付退貨運費.
保障：
請參閱物品說明或聯絡賣家以取得詳細資料。閱覽全部詳情查看保障詳情
（不符合「eBay 買家保障方案」資格）
物品細節
- 物品狀況
- 全新: 全新，未閱讀過和使用過的書籍，狀況完好，不存在缺頁或內頁受損。 查看所有物品狀況定義會在新視窗或分頁中開啟
- ISBN
- 9780521563086
- Subject Area
- History, Medical
- Publication Name
- Networks of Innovation : Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
- Publisher
- Cambridge University Press
- Item Length
- 9.3 in
- Subject
- United States / 20th Century, Preventive Medicine
- Publication Year
- 1996
- Type
- Textbook
- Format
- Hardcover
- Language
- English
- Item Height
- 0.8 in
- Item Weight
- 18.6 Oz
- Item Width
- 6.2 in
- Number of Pages
- 320 Pages
關於產品
Product Identifiers
Publisher
Cambridge University Press
ISBN-10
0521563089
ISBN-13
9780521563086
eBay Product ID (ePID)
469095
Product Key Features
Number of Pages
320 Pages
Publication Name
Networks of Innovation : Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
Language
English
Subject
United States / 20th Century, Preventive Medicine
Publication Year
1996
Type
Textbook
Subject Area
History, Medical
Format
Hardcover
Dimensions
Item Height
0.8 in
Item Weight
18.6 Oz
Item Length
9.3 in
Item Width
6.2 in
Additional Product Features
Intended Audience
Trade
Dewey Edition
21
Reviews
'The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.' John Hunt, The Pharmaceutical Journal, "Galambos and Sewell's well-documented book is a valuable and unusual contribution to the history of specialized pharmaceutical endeavor in America, with emphasis on the networking required on the long road leading to each new vaccine." Glenn Sonnedecker, American Historical Review, 'The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.'John Hunt, The Pharmaceutical Journal, ‘The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.’John Hunt, The Pharmaceutical Journal, "...best described by its subtitile because of the narrow focus on the chronological history of Merck's vaccine unit." Book Reviews, "Rigorously researched and crisply written, Networks of Innovation....makes a strong case for science-based firms' building and sustaining organizational capabilities to achieve technological innovation as well as to accomodate shifting competitive and regulatory environments." David B. Sicilia, The Journal of American History, "...this is a most impressive work....superb at showing the requisites for successful vaccine innovation. It provides outside observers rare insight into decision making processes at a leading pharmaceutical firm." Marvin Fischbaum, H-Net Reviews, "Networks of Innovation deserves a careful and thoughtful reading by historians of technology because it shows how it is possible to analyze effectively the role of individuals in the process of technological change without losing the insights and rigor that come from sociological and economic theory." W. Bernard Carlson, Technology and Culture
Illustrated
Yes
Dewey Decimal
615.1/9/00973
Table Of Content
Preface; 1. 1894: 'The foremost medical question of the day'; 2. The Mulford story; 3. A Sharp & Dohme interlude; 4. The virology network and a new programme at Merck, Sharp & Dohme; 5. Hilleman's innovations: first phase, measles-mumps-rubella; 6. Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama; 7. Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae; 8. New networks, new leadership: the Hepatitis B vaccines; 9. Vaccine innovation in the nineties: new strategies, new structures, and public confrontations; A word about sources.
Synopsis
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals., Networks of Innovation offers an historical perspective on how private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines, and how their activities were related to complex, evolving networks of scientific, governmental, and medical institutions., How private organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market antitoxins and vaccines., Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.
LC Classification Number
RM281.G35 1997
As told to
Sewell, Jane Eliot
賣家提供的物品說明
賣家信用評價 （2,579）
- 5***m (434)- 買家留下的信用評價。過去 1 個月購買已獲認證Excellent service, excellent condition
- o***i (213)- 買家留下的信用評價。過去 1 個月購買已獲認證Great